Merck product updates
Merck will be introducing a new RSV vaccine, Enflonsia, beginning July 21, 2025. Please let us know if you’re interested in learning more.
Additionally, Merck is offering discounts on Gardasil for eligible customers. Reach out to confirm eligibility or for more details.
RSV
If an office is interested in purchasing RSV vaccinations through the Child Health Advantage program, the office must hold a contract with the corresponding manufacturer. The available RSV vaccinations and age requirements are listed below.
To learn more about the vaccinations, please visit their respective websites or contact the office manufacturer rep. If an office wishes to get contracted with one of the following vaccinations, contact the Child Health Advantage program.
- Merck’s Enflonsia is available for children under 8 months of age born during or entering their first RSV season.
- GSK’s Arexvy vaccination is available for adults 50 and older.
- Pfizer’s Abrysvo vaccination is available for adults 60 and older. Abrysvo is also a maternal immunization available between 32 to 36 weeks during pregnancy.
- Sanofi’s Beyfortus vaccination is available during RSV season for newborns under one year old to children up to twenty-four months who are at high risk during RSV season.
